Rosuvastatin is an investigational HMG-CoA reductase inhibitor expected to gain FDA approval later this year for treatment of hypercholesterolemia. It has significantly exceeded atorvastatin, pravastatin, and simvastatin in reducing LDL cholesterol in clinical trials. This Focus article reviews those trials as well as rosuvastatin's pharmacologic and safety profiles in an effort to delineate its likely role in cholesterol-reducing therapy.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Rosuvastatin: A new HMG0CoA reductase inhibitor for hypercholesterolemia (PDF)

Newsletter